MucosaTec was invited to Venture SPRIND 2024 in Berlin on April 24th, 2024. The event will bring together over 300 business angels, VCs, and venture debt investors to meet 45 teams from the SPRIND portfolio. The presence of political guest Robert Habeck, German Federal Minister for Economic Affairs and Climate Action, adds even more significance … Read more
Bionity.com reports in the news about MucosaTec winning the Innovation Award 2024. MucosaTec’s technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections. The peptides bind to both the pathogen and the mucus, our body’s natural barrier, and thus immobilize pathogens. This innovation could form the basis for the … Read more
A major daily newspaper in Berlin, Germany, the “Berliner Zeitung”, reports on its homepage about MucosaTec winning the Innovation Award 2024. The BioRegions prize is awarded for outstanding research results and inventions with high innovation potential. MucosaTec’s technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections.
This first edition of the founders award will be awarded on June 26th, 2024 from 6:00 p.m. in the beautiful premises of the “Berliner Sparkasse am Wannsee” (Kronprinzessinnenweg 21). An event in this constellation marks a significant milestone for Berlin’s university start-up scene and shows the enormous potential that exists in Berlin. The best nine … Read more
The esteemed BioRegions Innovation Prize 2024 was proudly presented to the MucosaTec team. Our groundbreaking patent for bifunctional peptides showcases a revolutionary technology that offers a flexible and cost-effective approach to combating viral infections. These peptides bind to both pathogens and our mucus, effectively immobilizing pathogenes. The award ceremony for this prestigious recognition took place … Read more
MucosaTec GmbH is presented in the Journal “Potenzial” (english: Potential) in the section “Talente” (english: Talents). The Journal is published by the Company WISTA owned by the city of Berlin. MucosaTec GmbH is presented in a comprehensive article covering the scientific basis, Prof. Lauster and his team, locations of the start-up in Berlin and the … Read more
MucosaTec GmbH was created as a spin-off of the MucBoost project. In the challenge „broad-spectrum antivirals“ by SPRIND – the Federal Agency for Disruptive Innovation – Germany, our project MucBoost was one of the winners of the third stage. The official Homepage presents pictures of some team members at work in our beautiful labs and … Read more
The Newspage of the 5th biggest national Newspaper in Germany – Welt – presents our research and the planned product in another big article (Welt+ required). The topic is wrapped different this time to fit in their “Health” section relating to the beginning of flu-season in Germany. Estimated 1.4 million readers are reached with the … Read more
November is flu-season in Germany. Therefore the 5th biggest national Newspaper in Germany – Welt – got the great idea to present our research and the planned product in a big article in their “Knowledge” section of the printed version. Estimated 1.4 million readers are reached with the printed paper and the web services of … Read more
Tagesspiegel.de highlights, in an article, our success in winning a challenge by the SPRIND agency of the Federal Ministry of Education and Research of Germany, and introduces the unique mechanism of action of our nasal spray currently in development. This nasal spray presents a novel approach in the creation of antiviral agents. With a significant … Read more
© COPYRIGHT MUCOSATEC
